2. Signaling Pathways
  3. Anti-infection
  4. HPV

HPV

Human papillomavirus

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) that commonly causes skin or mucous membrane growths (warts). HPV is a virus with double-stranded circular DNA from the papillomavirus family. All HPVs have icosahedral capsids. HPV displays tropism toward the epithelial basal layer, which houses adult epithelial stem cells responsible for replenishing the epithelium with daughter cells. There are more than 100 varieties of human papillomavirus (HPV). Some types of HPV infection cause warts, and some (HPV 16 and 18) can cause different types of cancer, including cancers of the anus, penis, vagina, vulva and back of the throat (oropharyngeal). Worldwide, the risk of being infected at least once in a lifetime among both men and women is 50%. Vaccines can help protect against the strains of HPV most likely to cause genital warts or cervical cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10221
    Vorinostat
    		Inhibitor 99.95%
    Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.
    Vorinostat
  • HY-136465
    A2ti-1
    		Inhibitor 99.84%
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection.
    A2ti-1
  • HY-124379
    TPCK
    		98.55%
    TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the PDK1/Akt pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats.
    TPCK
  • HY-120599
    Sabizabulin
    		Inhibitor 99.00%
    VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer.
    Sabizabulin
  • HY-101795
    Larixyl acetate
    		Inhibitor 99.46%
    Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.
    Larixyl acetate
  • HY-101795R
    Larixyl acetate (Standard)
    		Inhibitor
    Larixyl acetate (Standard) is the analytical standard of Larixyl acetate. This product is intended for research and analytical applications. Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.
    Larixyl acetate (Standard)
  • HY-163901
    E6-272
    		Inhibitor
    E6-272 is an inhibitor for human papillomavirus 16 (HPV 16). E6-272 inhibits the proliferation of HPV-positive cells SiHa and CaSki with GI50 of 32 nM and 62 nM. E6-272 induces apoptosis in cell SiHa and CaSki.
    E6-272
  • HY-P10428
    E6AP-mimicking peptide
    		Inhibitor
    E6AP-mimicking peptide (compound 13) is a high-affinity, selective, irreversible and potent peptide-based covalent HPV16 E6 inhibitor targeting the 16E6 oncoprotein using a cysteine-reactive acrylamide warhead. E6AP-mimicking peptide has a Ki of 17 nM. E6AP-mimicking peptide targets all residues appearing in the binding pocket of E6 to disrupt the binding interface of 16E6 and E6AP. E6AP-mimicking peptide selectively binds and crosslinks to MBP-16E6 in PBS or a protein mixture.
    E6AP-mimicking peptide
  • HY-P1907
    Human Papillomavirus (HPV) E7 protein (49-57)
    		98.92%
    Human Papillomavirus (HPV) E7 protein (49-57) is the H-2d-restricted human papillomavirus (HPV) E749-57 epitope (short peptide spanning the 49th to 57th amino acid residues in the E7 protein).
    Human Papillomavirus (HPV) E7 protein (49-57)
  • HY-119098
    GSK983
    		Inhibitor 99.8%
    GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.
    GSK983
  • HY-107801
    Inosine pranobex
    		Inhibitor 98.11%
    Inosine pranobex is an orally active immunomodulator. Inosine pranobex has broad-spectrum antiviral activity. Inosine pranobex inhibits human immunodeficiency virus (HIV), herpes simplex virus (HSV), vaccinia virus (VACV), human tumor virus (HPV), Cytomegalovirus, influenza virus (INFV), parainfluenza virus (PIV), and Epstein-Barr virus .
    Inosine pranobex
  • HY-136466
    A2ti-2
    		Inhibitor 99.27%
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection.
    A2ti-2
  • HY-114698
    Retro-2 cycl
    		Inhibitor 99.17%
    Retro-2 cycl (RN 1-001) is a retrograde transport inhibitor with antiviral activity. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudoviruses, with an IC50 of 54 μM and 160 μM respectively.
    Retro-2 cycl
  • HY-115412
    Vorinostat-d5
    		Inhibitor ≥99.0%
    Vorinostat-d5 (SAHA-d5) is the deuterium labeled Vorinostat. Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.
    Vorinostat-d5
  • HY-109045
    Teslexivir
    		Inhibitor
    Teslexivir (BTA074) is a potent antiviral agent. Teslexivir is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an association that is a necessary step in the DNA replication and thus viral production for Human Papilloma Virus (HPV) 6 and 11. Teslexivir can be used for condyloma research.
    Teslexivir
  • HY-P1778A
    HPV16 E7 (86-93) (TFA)
    		99.54%
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas.
    HPV16 E7 (86-93) (TFA)
  • HY-14741
    Epetirimod
    		Inhibitor
    Epetirimod (S-30563; TAK-851) is an immune-response modifier, that ameliorates the cervical human papilloma virus (HPV) infection and cervical dysplasia.
    Epetirimod
  • HY-146033
    HPV18-IN-1
    		Inhibitor
    HPV18-IN-1 (Compound H1) is a potent inhibitor of HPV18. HPV18-IN-1 prevents cervical cancer cells from premature cell procession and abnormal proliferation. HPV18-IN-1 supresses E7-Rb-E2F cellular pathway and DNA methylation. HPV18-IN-1 has the potential for the research of cancer diseases.
    HPV18-IN-1
  • HY-109045A
    Teslexivir hydrochloride
    		Inhibitor 99.34%
    Teslexivir (BTA074) hydrochloride is a potent antiviral agent. Teslexivir hydrochloride is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an association that is a necessary step in the DNA replication and thus viral production for Human Papilloma Virus (HPV) 6 and 11. Teslexivir hydrochloride can be used for condyloma research.
    Teslexivir hydrochloride
  • HY-119151
    GS-9191
    		Inducer
    GS-9191 is the prodrug of the nucleotide analog PMEG. GS-9191 is a topical agent to permeate skin and be metabolized to the active nucleoside triphosphate analog in the epithelial layer. GS-9191 inhibits NA synthesis, arrests cell in S phase, and induces cell apoptosis. GS-9191 can be used for research of human papillomaviruses (HPV) infection.
    GS-9191
Cat. No. Product Name / Synonyms Species Source